Ira Winer, MD, PhD, Reviews Results of the ARTISTRY-1 Trial in Ovarian Cancer


Ira Winer, MD, PhD, FACOG, spoke about patients with pretreated platinum-resistant ovarian cancer treated with nemvaleukin alfa plus pembrolizumab in the phase 1/2 ARTISTRY-1 trial.

During The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, CancerNetwork® spoke with Ira Winer, MD, PhD, FACOG, a gynecologic oncologist at the Karmanos Cancer Center and associate professor in the Division of Gynecologic Oncology at Wayne State University in Detroit, about results from the phase 1/2 ARTISTRY-1 trial (NCT02799095) on the use of nemvaleukin alfa (ALKS 4230) plus pembrolizumab (Keytruda) in patients with pretreated platinum-resistant ovarian cancer.


The ARTISTRY-1 trial in and of itself was a phase 1 trial that included multiple different types of patients with different types of [solid] tumors. It was a combination of a dose-escalation design with nemvaleukin alfa, as well as dose-expansion [phase that examined both the] single agent but also dual agents of nemvaleukin alfa plus pembrolizumab. There were multiple different arms, but to go into the details of the entire trial is extensive.

If we want to focus specifically on ovarian cancer, there were a number of patients who were treated over the entire phase of the trial. The specific patients that we were focusing on [in the presentation at SGO 2022 were those] treated with nemvaleukin alfa plus pembrolizumab, and that was because ovarian cancer currently does not have an immuno-oncology FDA approval. There were a total of 16 patients, although there were 15 patients who were finally included in our analysis, who were heavily pretreated, and the vast majority [had serous tumors] although there were a couple of other tumor types.

Prior [lines of therapy] ranged anywhere between 3 and up to 9 or so. The number of prior lines [of treatment] for the vast majority, or over 50% of the patients, was greater than 5 lines of prior chemotherapy. That was a heavily pretreated group of [patients with] platinum-resistant disease. The overall findings were that we had a significant objective response rate as well as what I would call clinical benefit. The reason is there were 4 patients who had objective response, 2 with complete responses and 2 with partial responses. One of those partial responses was unconfirmed at the time of the publishing of this abstract, it’s been since confirmed. Of those patients who had objective responses, 3 were on [treatment] for a significant amount of time to greater than almost 2 years. If we’re looking at percentages, the objective response rate was about 30% or 28.5% to 29%. The control rate, though, was even more significant [at] over 70%. In fact, a couple of our patients did not have stable disease for well over a year.


Winer I. Clinical outcomes of ovarian cancer patients treated with the novel engineered cytokine nemvaleukin alfa in combination with the PD-1 inhibitor pembrolizumab: recent data from ARTISTRY-1. Poster presented at: 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022; Phoenix, Arizona.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Related Content